- Home
- VRAX vs DSS Comparison
VRAX vs DSS Comparison
Compare VRAX & DSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRAX | DSS |
|---|---|---|
| Founded | 2013 | 1984 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Containers/Packaging |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7M | 9.2M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | VRAX | DSS |
|---|---|---|
| Price | $0.19 | $0.83 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $1.00 | N/A |
| AVG Volume (30 Days) | ★ 5.3M | 15.6K |
| Earning Date | 03-10-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 42.45 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,085,000.00 |
| Revenue This Year | $217,274.83 | $14.93 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.15 | $0.72 |
| 52 Week High | $1.34 | $1.90 |
Technical Indicators
Market Signals| Indicator | VRAX | DSS |
|---|---|---|
| Relative Strength Index (RSI) | 48.50 | 47.00 |
| Support Level | N/A | $0.85 |
| Resistance Level | $0.25 | $0.97 |
| Average True Range (ATR) | 0.02 | 0.07 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 32.84 | 42.86 |
Price Performance
Historical ComparisonAbout VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
About DSS DSS Inc.
DSS Inc is operating a business focused on Five operating segments Product Packaging, Biotechnology, Commercial Lending, Securities and Investment Management, and Direct Marketing. Currently operates five distinct business lines operate around the globe with primary operations in North America and Asia. Product packaging manufactures, and sells sophisticated custom folding cartons, mailers, photo sleeves and complex three-dimensional direct mail solutions. Biotechnology division targets unmet, urgent medical needs and expands the borders of medical and pharmaceutical science. Commercial Lending through represents its banking and financing business line. Alternative Trading develops and/or acquires assets and investments in the securities trading and/or fund management arena.